Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOT106 in Advanced Unresectable or Metastatic Osteosarcoma and Soft Tissue Sarcoma
NCT07801222Phase 2Not yet recruiting
- Sponsor
- SOTIO Biotech
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of SOT106 in osteosarcoma (OS), soft tissue sarcoma (STS), sponsored by SOTIO Biotech. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SOT106
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07801222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801222.